Atara Biotherapeutics Inc
Change company Symbol lookup
Select an option...
ATRA Atara Biotherapeutics Inc
PBA Pembina Pipeline Corp
ZTS Zoetis Inc
HMPT Home Point Capital Inc
KWR Quaker Chemical Corp
TWO Two Harbors Investment Corp
BV Brightview Holdings Inc
PBPB Potbelly Corp
RLJ RLJ Lodging Trust
LHCG LHC Group Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Closing Price
$12.89
Day's Change
-0.61 (-4.52%)
Bid
--
Ask
--
B/A Size
--
Day's High
13.77
Day's Low
12.67
Volume
(Heavy Day)
Volume:
1,965,664

10-day average volume:
917,774
1,965,664

Display:

Providers:

UpdateCancel
6 providers
May 04, 2021
Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and...(BusinessWire)

Atara Biotherapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 4, 2021 / Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 4, 2021 at 4:30 PM Eastern Time. (Accesswire)

April 27, 2021
Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and...(BusinessWire)

April 02, 2021
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and...(BusinessWire)

March 14, 2021
Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel(R) Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and...(BusinessWire)

March 09, 2021
Atara Biotherapeutics to Participate in Virtual 33rd Annual ROTH Conference

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and...(BusinessWire)

March 05, 2021
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and...(BusinessWire)

March 01, 2021
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress

--On track with ATA188 Phase 2 RCT (randomized controlled trial) enrollment in patients with progressive forms of MS, enabling an interim analysis in H1 2022 --Continued progress on advancing CAR T portfolio, enabling clinical data presentation for...(BusinessWire)

Atara Biotherapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 1, 2021 at 4:30 PM Eastern Time. (Accesswire)

February 18, 2021
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and...(BusinessWire)

February 08, 2021
Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel(R) and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience

--Atara partnered with CareDx on an innovative testing solution that enables detection and quantification of non-engineered allogeneic T-cell therapies and establishes this as a sensitive and precise method for use in ATA188 clinical development (BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.